 Engineering HBV specific T cells utilizing a chimeric antigen receptor or a classical T cell receptor provides a well characterized sizeable and functionally intact population of HBV specific T cells with identical

@highlight Current anti HBV therapy suppresses but does not cure HBV infection.
@highlight Reconstitution of HBV specific immunity is an essential step to attain HBV cure.
@highlight Engineering T cells with HBV specific CAR TCR generates a functionally intact HBV specific T cell population.
@highlight HBV features make it an appropriate target for T cell therapy.
@highlight Electroporation of mRNA TCR produces HBV T cells with safer clinical profile.
